Surgical treatment for epilepsy: the potential gap between evidence and practice by Jette, N et al.
1 
 
 
 
TITLE 
Surgical treatment for epilepsy: the potential gap between evidence and practice 
 
AUTHORS 
Nathalie Jetté FRCPC1,2 Josemir W. Sander FRCP,3,4 Mark R. Keezer MDCM3-5  
 
1 Department of Clinical Neurosciences and Hotchkiss Brain Institute, University of Calgary, 
Alberta, T2N 2T9, Canada. 
2 Department of Community Health Sciences and O’Brien Institute for Public Health, University 
of Calgary, Alberta, T2N 2T9, Canada. 
3
 NIHR University College London Hospitals Biomedical Research Centre, UCL Institute of 
Neurology, Queen Square, London, WC1N 3BG, and Epilepsy Society, Chalfont St Peter, SL9 
0RJ, UK. 
4 Stichting Epilepsie Instellingen Nederland (SEIN), Heemstede 2103SW, The Netherlands. 
5
 Centre hospitalier de l’Université de Montréal (CHUM), Hôpital Notre-Dame, Montréal, 
Québec, H2L 4M1, Canada. 
 
CORRESPONDING AUTHOR:  
Ley Sander 
Box 29, UCL Institute of Neurology, Queen Square, London WC1N 3BG, UK 
telephone: +44 20 3448 8622 
email: l.sander@ucl.ac.uk  
  
2 
 
 
 
SUMMARY 
Randomised controlled trials, along with more than one hundred case series and observational 
studies, support the efficacy and safety of resective surgery, and more recently non-resective 
interventions, for the treatment of drug resistant epilepsy in appropriately selected individuals. 
There is an argument that epilepsy surgery remains underused. The evidence to support this 
assertion is at times opaque. Recent longitudinal studies show a stagnant or decreasing rate of 
epilepsy surgery over time, despite the evidence and guidelines supporting its use. Some suggest 
that this stagnation is due to a decreasing pool of eligible surgical candidates. Others emphasise 
the numerous barriers to epilepsy surgery. Strategies exist to increase access and better 
communicate the efficacy of this potentially life-changing procedure. The further investigation of 
the nature and causes of the presumed underuse of epilepsy and the elaboration of strategies to 
address this treatment gap, are necessary and pressing. 
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Epilepsy affects at least 70 million people worldwide.1 The prognosis for seizure remission for 
many individuals with epilepsy is favourable. In community-based cohorts, 60% of people will 
experience at least 5-years of remission during the first 9 years of their disease2 although data 
suggests that this proportion may be much lower in people with focal, rather than generalised, 
epilepsy. 3 
Epilepsy is pragmatically defined as “drug resistant” when it remains uncontrolled despite two 
adequate trials of antiepileptic drugs (AEDs) that were appropriate for that person’s epilepsy.4 It 
is estimated that approximately 30% of individuals with epilepsy are drug resistant.5 Such 
individuals are a great challenge for attending physicians. Not surprisingly, increased seizure 
frequency and severity, as well as AED polypharmacy are important drivers of health-related 
quality of life, resource use, and costs.6 Eighty percent of direct and indirect costs of illness in 
epilepsy are accounted for by people with drug resistant epilepsy.7 Premature mortality is more 
common in people with epilepsy as compared to the general population,8 and individuals with 
more severe epilepsy are at greater risk of seizure-related injuries. Sudden unexpected death in 
people with epilepsy (SUDEP) is described as an important cause of epilepsy-related mortality.9 
The risk can be 0.9 per 1,000 person-years in low-risk populations,10 but the odds of SUDEP 
increase by over 20-fold in those with uncontrolled convulsive seizures and AED 
polypharmacy.11 
Since the initial work performed in the late 19th century, resective surgical procedures, excising 
putative epileptogenic foci, is an important intervention in the management of people with 
epilepsy.12,13 Recent work emphasizes that epilepsy surgery can be a powerful means of treating 
people with drug resistant epilepsy, that it should not be viewed as a “last resort”.14 Despite our 
long familiarity with epilepsy surgery, a number of experts argue that epilepsy surgery remains 
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underused.15,16 Epilepsy surgery has been described as “arguably the most underutilized of all 
accepted therapeutic interventions in the entire field of medicine.”17  
In this Personal View, we discuss data addressing the efficacy, risks, and alternatives to resective 
epilepsy surgery. We then synthesize the evidence regarding patterns of use of epilepsy surgery, 
explore potential barriers, examine strategies to increase access to epilepsy surgery, and propose 
future directions for the study of this potentially life-saving, and life-changing, procedure. 
 
The scope  
We are acutely aware of the enormous epilepsy treatment gap, defined as the proportion of 
individuals who require but do not receive medical or surgical treatment, in low and middle-
income countries (LMIC).18 In many such countries, the epilepsy treatment gap is above 75%.18 
A World Health Organisation survey of health care providers carried out in 2005 reported that 
while there is an average of one neurologist per 100,000 persons in Europe and North America, 
this number plummets to less than one per million in sub-Saharan Africa and Southeast Asia.19 
Computerised tomography scans and electroencephalography are available in 96% and 92% of 
countries in the Americas, respectively, but only 67% and 78% of countries in Southeast Asia. 
The situation with respect to magnetic resonance imaging is particularly dire.19 It is not 
surprising; therefore, that epilepsy surgery is performed in less than 20% of low-income 
countries.19,20 Adherence to prescribed therapy is also particularly low in LMIC countries, related 
to availability, accessibility, and affordability of epilepsy-related healthcare resources, but also 
the lingering effects of the stigma of epilepsy, lack of awareness, and associated negative 
attitudes towards epilepsy and Western medicine. These issues make an examination of the use 
of epilepsy surgery in LMIC countries quite distinct. For this reason, as well as the dearth of data 
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with reference to epilepsy surgery in such settings, we chose to focus this review primarily on 
high-income countries. 
 
The benefits of epilepsy surgery 
Seizure outcomes after resective surgery  
Resective epilepsy surgery was first introduced in the late 19th century, although our modern 
approach, including the important role of electroencephalography, was developed later in the 
1940’s.12,13 Over the ensuing decades, the practice of epilepsy surgery developed and expanded, 
its efficacy described in an ever growing number of case series and observational studies, of 
which there are now over one hundred.21 The most cited randomized controlled trial (RCT) of 
epilepsy surgery compared the efficacy of anterior temporal lobectomy (ATL) to medical 
management alone in people with drug resistant mesial temporal lobe epilepsy.22 In this single-
centre study of 80 individuals, 23 of 40 (58%) individuals were free of seizures impairing 
awareness one year after surgery compared to 3 of 40 (8%) individuals in the medical group 
(intention to treat analysis). A more recent multi-centre RCT limited to individuals with newly 
diagnosed drug resistant epilepsy, failed to meet its recruitment target (n = 38) and was 
terminated early, but nevertheless showed that 11 of 15 (73%) of those in the surgical group 
were free of disabling seizures at two years’ follow-up, as compared to no one in the medical 
group.23  
There are also five other RCTs of resective epilepsy surgery comparing the efficacy of different 
surgical approaches rather than comparing surgical to medical management. Four of these RCTs 
compared resections of different extent in people with temporal lobe epilepsy (ie temporal 
lobectomy with or without sparing of the superior temporal gyrus, 2·5 vs 3·5 cm anterior 
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temporal resection, temporal lobectomy with partial vs complete hippocampectomy, and 
temporal lobectomy with or without anterior corpus callosotomy in people with developmental 
delay).24-27 None of these RCTs reported statistically significant differences in seizure outcome 
except for the study comparing temporal lobectomy with partial vs complete hippocampectomy 
where the proportion of seizure free participants was greater in the complete resection group [25 
of 36 (69%) vs. 13 of 34 (38%)] without differences in neuropsychological outcomes.26 Finally, 
an RCT of transcortical vs transsylvian selective amygdalohippocampectomy (SAH) did not find 
any differences in seizure freedom between both approaches but cognitive outcomes 
(improvement in fluency) were better in the transcortical group.28 There remains controversy 
whether en bloc ATL and SAH are equally effective, with some meta-analyses showing SAH as 
more effective,29 others that ATL is more effective,30 and others with no evident difference.31  
A recent Cochrane systematic review and meta-analysis of RCTs and observational studies 
showed that, after analysing 177 studies including 16,253 people, resective epilepsy surgery 
overall increased the probability of a person being free from seizures impairing awareness at one 
year by almost eight-fold and of being free from all seizures by 15-fold.21 Overall, the quality of 
the included observational studies was judged to be very low while the first RCT to compare 
surgical to medical treatment22 was judged to be of moderate quality.  
The benefits of epilepsy surgery are not universal, varying to an important degree between 
different epilepsy populations. The existing RCTs comparing surgical to medical treatment were 
carried out in selected people with mesial temporal lobe epilepsy.22,23 Subgroup analyses in the 
Cochrane review showed that the presence of mesial temporal sclerosis is associated with a 17% 
relative increase in the chance of good post-surgical outcome, while the absence of MRI 
evidence of a focal abnormality decreases the relative probability of good outcome by over 
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20%.21 A separate meta-analysis drew a similar conclusion about the superior outcome among 
those with so-called “lesional” versus “non-lesional” epilepsy.32 Lesser, but arguably still 
favourable, outcomes among those with non-lesional extratemporal lobe (ie, frontal, occipital, 
and parietal) epilepsy are reported, with an overall probability of seizure freedom one year or 
more post-surgery of 45% in adults33 and 34% in children.34  
Long-term post-surgical outcomes 
There is less evidence about the long-term outcomes of epilepsy surgery. One prospective cohort 
study of 615 adults (the majority of whom underwent temporal lobe resections) showed that 52% 
of individuals remained free of disabling seizures five years after surgery and 47% at 10 years.35 
Seizure recurrence was two-fold higher among those with extratemporal resections as compared 
to those with ATLs. A meta-analysis of observational studies and case series (n = 71 studies, 
only six with a control group) showed that the overall long-term (ie, mean/median 5 years after 
surgery) probability of becoming seizure-free was 66% following temporal lobe resections 
(similar to the short-term outcome per-protocol analysis results of the seminal RCT22), 46% for 
occipital and parietal lobe resections, and 27% with frontal lobe resections.36 
The accepted indications for an epilepsy surgery evaluation are given in Table 1. 
Benefits beyond seizure frequency 
The benefits of epilepsy surgery are not limited to seizure frequency. Epilepsy surgery was 
recently reported in the largest clinical cohort to result in a significant decrease in the mortality 
rate, as compared to people who did not undergo surgery.37 This effect was most pronounced 
when examining those who were post-surgically free of generalised tonic-clonic seizures.37 
Simulation models suggest that epilepsy surgery increases life expectancy by an average of five 
years.38,39 Other investigators demonstrate additional benefits to cognition,40 social outcomes (eg, 
8 
 
 
 
self-reported improvements in relationships, independence and overall lifestyle),41 as well as 
psychiatric comorbidities.42 Epilepsy surgery is also cost effective, associated with savings in 
direct medical costs of almost U$ 1,500 per patient over 18 to 24 months in one study 43 and as 
high as almost U$ 7,000 per patient-annum over an average of five years in another.44 
 
The risks of epilepsy surgery 
Medical and neurological complications 
Most post-surgical complications in those who have epilepsy surgery are minor and tend to be 
associated with complete resolution.45 According to one meta-analysis, major and minor medical 
complications occur in 2% and 5% of individuals.45 Major medical complications include 
hydrocephalus and intracranial abscesses requiring surgical intervention. Minor medical 
complications are cerebrospinal fluid leaks, infection, aseptic meningitis, deep vein 
thrombosis/pulmonary embolism, pneumonia, intracranial haematomas, and metabolic 
disturbances. Major and minor neurological complications, on the other hand, occur in 5% and 
11% of individuals. Minor neurological complications are those that resolve within three months 
of their onset while those that persist are considered major complications. The most common 
neurological complications are visual field defects involving one quadrant or less (occurring in 
13% of persons) whilst 2% experienced hemianopia. Mild or temporary aphasia occur in 4% of 
individuals and more severe aphasia occur in less than 1%.45 Complications tend to be more 
common in children and in those who undergo extratemporal resection.45 Mortality is extremely 
rare.45  
Neuropsychological and psychiatric complications 
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Apart from potential medical and neurological complications, there are possible 
neuropsychological sequelae to epilepsy surgery. One meta-analysis reported that among those 
undergoing ATL, verbal memory deficits occur in 44% of individuals post left-sided surgery and 
20% post right-sided surgery.40 Declines in visuospatial memory are reported in approximately 
20% of individuals overall, irrespective of the side of surgery.40 It is important to note that 
paradoxical gains in neuropsychiatric function are also reported: 7-14% for verbal memory and 
10-15% for visuospatial memory.40 Naming is decreased in 34% of left-sided surgeries but 
fluency is increased in 27%.40 There have been reports of de novo mental health disease, 
especially among those with persistent post-operative seizures. These ranged from relatively 
mild conditions such as interictal dysthymic disorder among 18% of persons, to more severe 
psychosis but in only 1% of persons.42 In general, however, studies report no changes or 
improvement in psychiatric outcomes after epilepsy surgery.42  
Effects of medical centre experience 
Most data on epilepsy post-surgical outcomes come from experienced, high-volume centres. 
Positive correlations between medical centre case volume and clinical outcome and mortality 
have been reported in oncological and cardiac surgery.46,47 It is reasonable to question whether 
outcomes following epilepsy surgery in low-volume centres are as favourable as those in high-
volume centres. Little data on this exist, with the exception of one USA study examining 6652 
complete or partial lobectomies to treat epilepsy at 650 hospitals between 1990 and 2008. This 
study showed a statistically significant increase in the risk of post-operative adverse events when 
comparing high-volume centres (> 15 surgeries per annum) and low-volume centres (< 5 
surgeries per annum), from 6·1% to 12·9%.48  
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Seizure reduction versus elimination after epilepsy surgery  
More and more epilepsy surgery experts support the concept that epilepsy surgery seems to 
convert drug resistant epilepsy to drug responsive epilepsy. The proportion of people who are 
able to come off AEDs after surgery has not been studied prospectively or in an RCT. It is 
estimated, however, that up to 25% of people are seizure free and off AEDs after resective 
surgery,49 which still leaves many who require ongoing management with AEDs to control their 
seizures or who prefer not to discontinue medical treatment. Seizure outcome after surgery is 
typically linked to the complexity of the epilepsy syndrome.49 Similarly, the extent of the 
epileptogenic network on imaging is inversely related to seizure outcome in those with newly 
diagnosed epilepsy.50 In cases of complex epilepsies, resective surgery likely interrupts the 
epileptogenic network but does not address molecular or structural changes beyond the resected 
site.51 In such cases, seizures may recur after AED withdrawal or reduction, but in one study 75 
of 112 (67%) became seizure free again after restarting AEDs, supporting the concept that 
surgery converted them from being drug resistant to drug responsive to AEDs.52 
 
Alternatives to resective surgery 
It is important to note the growing number of non-resective surgical approaches to treat drug 
resistant epilepsy introduced in recent years. These procedures include ablative interventions 
[gamma knife radiosurgery (one RCT),53 laser interstitial thermal therapy (no RCT)]54 as well as 
neuromodulation interventions such as cerebellar stimulation (one RCT),55 hippocampal 
stimulation (two RCTs),56,57 repetitive transcranial magnetic stimulation (one RCT),58 responsive 
neurostimulation (one RCT),59-61 thalamic stimulation (one RCT),62 trigeminal nerve stimulation 
(one RCT),63 and vagal nerve stimulation (six RCTs).64-69 These interventions are evolving 
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rapidly and for some individuals represent a less invasive and a more acceptable approach as 
compared to resective surgery. Table 2 demonstrates the advantages and disadvantages of 
various resective, ablative and neuromodulatory approaches used in the treatment of temporal 
lobe epilepsy.70 Unfortunately, despite the effectiveness of some non-resective interventions, the 
heterogeneous reporting of seizure outcome (different endpoints) between ablative and 
neuromodulation studies makes it impossible to determine the comparative effectiveness of these 
devices and an RCT comparing their effectiveness to resective surgery is lacking. It is likely as a 
result of this lack of evidence that resective surgery represents the great majority of surgical 
interventions in epilepsy.71 For this reason, we focus on resective approaches in our evaluation of 
the use of epilepsy surgery.  
 
The use and underuse of epilepsy surgery 
The epilepsy surgery treatment gap  
Evaluating how the provision of resective epilepsy surgery compares to the requirements of 
those with drug resistant focal epilepsies has proven to be a great challenge, with discordant 
results. An often cited report on the epilepsy surgery treatment gap concluded that “surgical 
activity” must more than triple again just to accommodate the annual increment, let alone to 
address the backlog.”72 This conclusion was based on the comparison of the number of epilepsy 
surgeries reported in a 1992 voluntary survey of large number of USA epilepsy centres, to a 
1990 National Institutes of Health estimate of the nationwide number of surgical candidates.73 
One prospective survey of all adult and paediatric epilepsy surgeons in the UK, on the other 
hand, found that the 422 surgeries performed in 2000 were, when compared to estimates derived 
from the UK National General Practice of Epilepsy, almost sufficient to at least accommodate 
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the estimated 450 new surgical candidates who accrued over this same period.74 A recent 
retrospective population-based cohort study using administrative data showed that only 1·2% of 
individuals with drug resistant epilepsy underwent epilepsy surgery during a two-year 
observational period.75 This study had limitations, however, as have been outlined by others76 
and was unable to provide a sense of how this surgery rate corresponded to population 
requirements. Other research groups report that approximately 1·5 to 3% of individuals in the 
general population with incident epilepsy require epilepsy surgery74,77 although much work to 
further examine the number of potential surgical candidates in the general population is still 
required. 
Referral patterns for epilepsy surgery 
Direct evidence of the underuse of epilepsy surgery is sparse. There is, however, definite 
evidence of under-referral and significant delays in the referral of suitable candidates for 
epilepsy surgery evaluation. A 2001-2002 population-based Swedish study demonstrated that of 
88 individuals with severe focal epilepsy in a relatively closed population, up to 40% were not 
appropriately referred to an epilepsy centre.78 A Dutch cross-sectional study in 10 hospitals 
showed that 63% (116 of 185) of prevalent “candidates for screening” were similarly not 
referred.79 Intractable epilepsy becomes evident within an average of nine years after disease 
onset80 but the referral delay for a surgical evaluation is approximately 20 years in adults.80-82 
This referral delay has remained largely stable over the last several decades,81 or even slightly 
increased.83,84 
Some of the apparent underuse of epilepsy surgery may reflect that epilepsy is a dynamic 
condition in some, alternating between drug responsive and drug resistant states. Temporary 
remission may reduce enthusiasm for epilepsy surgeryfor many individuals and health 
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professionals. An often cited report describes that among those with previously untreated 
epilepsy, 60% will become seizure-free for at least one year, during a median period of five 
years, while treated with either their first or second AED.5 Twenty percent of such individuals, 
however, who do not respond to either their first or second AED will go on during a seven-year 
period to enjoy at least one-year terminal remission of their epilepsy; a further 30% will 
experience a 50% reduction in their seizure frequency.85 According to one study, approximately 
5% of people who fail to respond or tolerate at least two AEDs go on to achieve a 6-month 
terminal seizure remission annually, with further medication adjustments.86 On the other hand, 
epilepsy remains unpredictable and seizure-remission may be short-lasting. Among people with 
epilepsy and five years of seizure freedom in one clinic-based series, 40% went on to have at 
least one recurrent seizure.87 A community-based and prospective cohort study examining cases 
of incident epilepsy reported that almost 60% of children entered into a one-year remission but 
that 70% of them later relapsed during a median follow-up period of 10 years.88 
Temporal trends in epilepsy surgery 
Not necessarily evidence of underuse but important insights are nevertheless gained from an 
examination of temporal trends in the practice of epilepsy surgery. Administrative data from the 
Nationwide Inpatient Sample (NIS), which includes databases from a 20% random-sample of all 
non-federal USA hospitals, collected between 1998 and 200889 and 2009,90 reported that the use 
of epilepsy surgery has failed to increase over time. This was found despite a paradoxical 
increase in the number of hospitalizations for focal epilepsy, which doubled over this same time 
period, to approximately 8000 per year (Fig. 1a).89,90 A UK survey of adult and paediatric 
epilepsy surgeons (a follow-up study to the 2000 survey described above)74 not only failed to 
show an increase in the number of surgeries, but instead reported a meagre 246 surgeries 
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(excluding vagal nerve stimulators) nationwide over a 12-month period in 2010-2011, a dramatic 
40% decrease from 10 years prior.71 Data from the Swedish National Epilepsy Surgery Register 
demonstrated a similar decrease in the number of surgeries per annum over time, from 78 in 
1991 to 50 in 2007.91  
It is important to note that much of the data available on current utilisation patterns for epilepsy 
surgery are drawn from retrospective administrative databases which are prone to 
misclassification errors due to difficulties in identifying individuals with incident epilepsy 
(versus prevalent cases), those with drug resistant epilepsy, and those who have previously 
undergone epilepsy surgery; higher quality data are therefore urgently required. Any changes or 
lack thereof, in the rate of epilepsy surgery may be due to fluctuations in spurious observations 
rather than actual outcomes. Other potential explanations for the observed temporal trends in 
epilepsy surgery exist (Table 3). One possibility is that the observed trends result from a shift in 
where epilepsy surgery is performed, from a small number of high-volume centres to a larger 
number of low- and middle-volume centres. For example, data from US hospitals showed that 
between 1990 and 2008 the number of hospitalisations increased more than two-fold more at 
low- and middle-volume centres (performing less than five or 15, respectively, procedures per 
year), as compared to high-volume centres, with a corresponding shift in the number of 
lobectomies (Fig. 1b).48 Such lower-volume centres appear to operate on a smaller proportion of 
hospitalisations,48 which may be as a result of insufficient resources and expertise.92  
Some investigators suggest that the apparent reduction in the use of epilepsy surgery over time is 
also potentially due to a depletion of eligible candidates for epilepsy surgery from the general 
population.71 Indirect evidence of this may be the decreasing number of standard temporal lobe 
surgeries performed84,93,94 despite the greater use and availability of video-EEG monitoring.90 
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The increasing delay between epilepsy onset and surgery reported by some83,84 may also indicate 
a depletion of optimal candidates and an increasing focus on more challenging cases, an opinion 
held by many experts.95 The pool of surgical candidates may be depleting as a direct result of the 
increasing success of medical treatment. Some evidence exists to support a modest improvement 
in efficacy when comparing newer to older generation AEDs.96-98 It could also be argued that 
with a greater number of AEDs currently available in the armamentarium the total number of 
people who benefit from drug treatment has increased even if the results from each individual 
drug are modest. The pool of adult surgical candidates may also be decreased due to successes in 
paediatric populations. In the face of stagnant or decreasing rates among adults, the rate of 
epilepsy surgery among children has increased over the last few decades.90,93,99 Of 3,621 
procedures reported in 2012 by one USA study, 1,110 were among children.93 Over 12 months 
(2010-2011) in the UK, 238 procedures were performed in children and 472 were performed in 
adults.71 It has been suggested that improved management of febrile seizures and febrile status 
epilepticus in children has also helped decrease the number of adults with drug resistant 
epilepsy,93 which may explain the particular decrease in surgery for mesial temporal sclerosis 
(MTS) over time which has been observed by a number of investigators.84,93,94 
Any proposed decrease in the pool of eligible, and identified, candidates for epilepsy surgery is 
not discordant with its persistent underuse. Such an observation may reflect that the identified 
and generally considered pool of eligible individuals is decreasing all the while an even larger 
pool of individuals, who would be potential candidates, never receive the consideration they are 
due. 
 
Factors that influence use of epilepsy surgery  
16 
 
 
 
Facilitators to surgery 
Definite estimates on the use and probable underuse of surgery are sparse but evidence exists 
reporting many barriers and, less so, facilitators to epilepsy surgery. Patient facilitators to surgery 
include that they are more disabled by their epilepsy (more frequent and severe seizures, 
frustration with epilepsy, stigma, embarrassed to have seizure in public, etc.)100 and have a strong 
desire to be seizure-free to improve their psychosocial outcomes (eg, work and driving 
opportunities).101-104 The availability of less invasive surgical approaches as discussed earlier 
(ablative, neuromodulation) with potentially similar effectiveness (better or same seizure 
outcomes and less adverse events) is a promising facilitator to epilepsy surgery that requires 
further investigation. 
Barriers to surgery 
There are strikingly more barriers than facilitators to epilepsy surgery. The main barriers to 
epilepsy surgery usually originate from the patient/family or from the physician/health system, 
though societal barriers also exist (Table 4). Barriers to epilepsy surgery include lack of 
knowledge and misconceptions about epilepsy surgery, behavioural and cultural issues, access 
issues, and research gaps. There are also significant disparities in care related to epilepsy 
surgery. Fear and anxiety are major factors influencing individuals’ decision to proceed with 
surgery.100,104,105 This is presumably in large part driven by a lack of knowledge and by the 
observation that many overestimate the risk of surgery.14,106 People with epilepsy describe it 
often as a very dangerous intervention that should only be considered as a last resort measure, 
including 73% of those in one Italian study.100,104,105,107-110 Mistrust of physicians likely plays a 
major influence as well.105 In one Canadian study, however, more than 90% of participants 
reported that they generally trust their physician.108 In a smaller USA study, people listed their 
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epilepsy physician (52·2%) followed by their neurosurgeon (34·8%) as the main source of 
information about epilepsy surgery and indicated that their epilepsy physician was the most 
influential in their decision to pursue surgery.100 It is thus imperative for physicians to be well 
informed about the risks and benefits of epilepsy surgery as they can play a major role in helping 
individuals reach an informed decision with regards to epilepsy surgery that is devoid of 
misconceptions.108 There is, however, a serious knowledge to action gap about the benefits of 
epilepsy surgery among physicians who are not epilepsy specialists, including some neurologists, 
and many still do not refer people with epilepsy for surgical consideration or have negative 
attitudes towards or misconceptions about the risks of epilepsy surgery.14,106 For example, 30% 
of children in one USA study were referred by a non-neurologist directly to a neurosurgeon for 
epilepsy surgery consideration rather than an epileptologist.107 One study in Michigan found that 
11% of neurologists who responded to the survey (response rate 20%) never discuss epilepsy 
surgery with their patients and almost 20% said that all AEDs had to fail before considering an 
individual to be drug resistant.111 This is concordant with an Italian study that reported that 60% 
of child neurologists do not follow treatment guidelines for epilepsy.110 Many child neurologists 
reported not recommending surgery even when MTS-like changes are present on MRI as well as 
suggesting that an individual should only be referred after failing at least five AEDs.110 A recent 
Canadian study found that almost 22% of people with epilepsy had previously been discouraged 
from having epilepsy surgery, with neurologists as the main culprits 65% of the time.108 In most 
cases, however, neurologists discouraged surgery because the patient was not a surgical 
candidate. Epilepsy was more often inappropriately discouraged by a family member (eg, 
“Father suggested I wait a few years since science always is learning new techniques…”; 
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“Family and friends were concerned of dangers”) or the patient was “hoping for less invasive 
treatment”.108  
Other individual and societal factors that can be barriers to epilepsy surgery include stigma and 
negative attitudes towards epilepsy per se, poor access to care (ie, lack of transportation, inability 
to take time off of work or school, forgetting appointments due to cognitive deficits), 
depression/other comorbidities, and poor self-efficacy and self-management (Table 4).106 
Health system factors also contribute to the delay and/or underuse of epilepsy surgery. These 
include a lack of access to comprehensive epilepsy surgery centres, a problem that is particularly 
evident in low- and middle-income countries, where up to 80% of countries are yet to have 
tertiary and quaternary epilepsy care programmes.112 Issues with inadequate health resources, 
however, are prominent even in high-income countries, as shown in a Canadian national survey 
of neurologists where more than 75% of respondents identified this as the biggest barrier to 
epilepsy surgery.113 Perceived lack of communication between tertiary care epilepsy centres and 
community-based practices is also a potential barrier to referral for epilepsy surgery.14 
There are important disparities in epilepsy surgical care that require further exploration as well. 
In a number of USA studies, older people, those of African-American descent (also “non-
whites”), those with limited English-language proficiency, and those without private insurance 
represent a disproportionately small proportion of those who undergo surgery.89,100,114 A number 
of reasons for disparities by race include distrust of physicians, language barriers, and 
socioeconomic status (SES).106 Disparities in access to epilepsy surgery by insurance status are 
particularly evident in the USA where uninsured individuals rely on government programmes 
such as Medicaid. The above vulnerable populations have lower odds of undergoing epilepsy 
surgery, even in well-designed studies where key confounders are adjusted for.89,100,114 Even in 
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Canada where universal health care exists, increased delays in time to surgery were reported in 
children of lower SES.115 The authors also found that children of lower SES had poorer seizure 
outcome.115 Those with a lower IQ are generally less likely to have epilepsy surgery, though the 
proportion of those with an IQ < 70 who underwent epilepsy surgery in London, UK study 
increased from 3% to 10% pre and post 2000 (1988-2007).116 These barriers and disparities 
provide a strong foundation to guide future implementation strategies to address the many 
misconceptions about epilepsy surgery and to close the knowledge to action gap for those with 
epilepsy who may benefit from this efficacious intervention. 
 
Strategies to improve knowledge and referrals 
Patient and caregiver approaches 
Strategies to improve referrals for epilepsy surgery, using a multifaceted approach, are outlined 
in Fig. 2. Ultimately, the best way to develop a successful implementation strategy is to involve 
the target users early on. In people with epilepsy and their family/caregiver(s), knowledge can be 
increased using a variety of knowledge translation tools including online educational materials, 
written information in physician offices, webinars, podcasts, patient testimonials video, regional 
educational sessions, and social media. It is important to also educate the individual and their 
families about self-efficacy and self-management as having such skills will not only break down 
barriers to epilepsy surgery, but should also improve their overall health outcomes. 
Comorbidities should be managed in persons with epilepsy, especially depression, since it can 
otherwise be associated with poor adherence to treatment, increased seizure frequency, higher 
health resource utilization, and self-efficacy.117 Stigma interventions are also needed at every 
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level (patient, family, health professionals, and society) to remove barriers for people with 
epilepsy. 
Clinician and health system approaches 
For physicians, the implementation of best practices often occurs using clinical practice 
guidelines (CPGs). A number of CPGs for epilepsy exist, although relatively few with direct 
reference to epilepsy surgery.118 One of the first major formal CPGs in epilepsy surgery was 
published in 2003, under the auspices of the American Academy of Neurology, American 
Epilepsy Society, and American Association of Neurological Surgeons. This CPG recommended 
that individuals with “disabling complex partial seizures” be referred to an epilepsy surgery 
centre after failing to respond to AED therapy.119 Consensus statements and CPGs regarding 
epilepsy surgery have been published for paediatric populations120 as well as local organisations 
in the UK,121 France,122 and India.123  
Clinical practice guidelines improve processes of care and outcomes.124 They are, however, often 
poorly implemented, including in epilepsy, and still represent an “elusive target.”82,125,126 One 
strategy to improve their implementation is to incorporate them into electronic medical records 
(EMRs) and/or at the point of care. A systematic review found that the implementation of 
electronic CPGs improved universally processes of care.127 Ultimately, the only effective way to 
ensure guidelines are used in practice is to adapt them to the local context. A great framework 
that can be used to achieve this goal is the knowledge to action gap framework from the 
Canadian Institutes of Health Research in conjunction with the ADAPTE process, which 
involves decision-makers and end-users in the implementation process.128,129 Other strategies to 
increase knowledge about epilepsy surgery for physicians include prompts embedded in EMRs, 
online tools, webinars, and podcasts. Pay per performance programmes can help “persuade” 
21 
 
 
 
physicians about the importance of adhering to best practices. Participation of physicians in 
mobile clinics and telehealth can also increase access to care for persons with epilepsy, to 
facilitate the road to epilepsy surgery. 
Another approach to improving access to epilepsy surgery by targeting physicians is to provide 
innovative, evidence-based means of predicting post-surgical outcome. Predictors of post-
surgical freedom have been described.130 Recently, investigators began to translate this 
knowledge into more clinically useful instruments, in the form of predictive scores131,132 or 
graphical nomograms.133 The goal is that such instruments will encourage and facilitate primary 
and secondary care providers to refer potential candidates for an evaluation at a tertiary or 
quaternary epilepsy centre. Similarly, clinical decision making tools can also facilitate clinical 
care. An online clinical decision tool was developed (www.toolsforepilepsy.com) to assist 
physicians who are not epilepsy experts in determining who should be referred for an epilepsy 
surgery evaluation.134 The tool is publically available, easy to use, and its feasibility (Canada and 
Germany) was determined to be very good.135,136 The tool is now being translated into 15 
languages, with its broad implementation across Canada and Europe in planning, although its 
final impact on clinical practice remains to be studied. Nevertheless, many examples of the 
successful implementation of clinical decision rules in neurology, especially in the stroke field, 
exist and suggest that such tools can improve outcomes with the right implementation science 
strategy.137,138 
Society and community-level approaches 
Strategies at the community/societal level must also be considered to increase access to epilepsy 
surgery (Fig. 2). Engaging lay organizations to help promote health policy in collaboration with 
medical professional organization can be beneficial. A number of key policies such as anti-
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discrimination policies at work, in schools, and sick leave policies should be considered.106 
Improved public transportation with discounted fares would help reduce transportation barriers 
so those with epilepsy who cannot drive can still attend medical appointments.106 Increased 
funding for research to develop better diagnostic tools to clearly delineate the epileptogenic zone 
and to determine the comparative effectiveness of less invasive surgical approaches relative to 
resective surgery would be beneficial. Improved seizure outcomes using less invasive 
interventions with minimal adverse events (e.g. better cognitive outcomes) would promote 
utilization of epilepsy surgery. 
 
Future directions 
Among carefully selected candidates, epilepsy surgery is efficacious and safe. There is a 
persistent and likely underuse of epilepsy surgery. There is evidence of under- and delayed-
referral of potentially appropriate individuals with drug-resistant epilepsy. High quality 
population-based data remain sorely needed to determine the true proportion of those with 
epilepsy who are possible surgical candidates and who do or do not undergo successful epilepsy 
surgery. Without a carefully designed prospective study where multiple sources of ascertainment 
are used along with collaboration from an interdisciplinary team (from primary care to 
neurosurgeons), we may never know the answer to the questions: Is the rate of epilepsy surgery 
really decreasing and, if so, why? How many people with epilepsy are never referred to a 
neurologist for epilepsy care? How many are followed by neurologists, are appropriate surgical 
candidates, but are never referred to an epilepsy centre? When individuals are referred and 
deemed appropriate candidates for surgery, why do they sometimes decline to have surgery? 
This needs to be carefully documented at the point of care.  
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There is also an urgent need to close the knowledge to action gap and break down the barriers to 
epilepsy surgery by following an integrated knowledge translation multipronged intervention 
approach107 (including decision aids for individuals and physicians)104 where people with 
epilepsy, support groups, physicians, policy makers, and researchers work together to ensure that 
those who are appropriate for epilepsy surgery are referred in a timely manner, using a shared 
decision-making process. This will also require improving education to reduce physician 
misconceptions about surgery, and patient education to reduce the fears and anxiety they face 
surrounding epilepsy surgery.103 We have at our disposal what is an efficacious treatment 
although our knowledge about the comparative effectiveness of various surgical therapies is 
limited. Nevertheless, in those in whom epilepsy surgery is appropriate, it is our obligation as a 
community to ensure that it is used to the fullest possible extent, to both change and save 
individuals’ lives. 
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Search Strategy 
We searched the electronic database PubMed (up to May 31, 2016) with the following keyword 
search strategy: (epilep* or convuls* or seizure*) AND surgery AND (underutilization OR 
underutilization OR utilization OR utilization OR underuse OR delay OR timely OR dispariti* 
OR treatment gap OR barrier* OR perception* OR attitude* OR decision-making OR prognostic 
tool OR decision analysis or comorbid*). The search was not limited by language of publication. 
Our search identified 1672 records. The title and abstract of each record were screened by one 
author (NJ). Additional articles were identified from the authors’ own files and from chosen 
bibliographies. The articles in this Review were included at the authors’ discretion on the basis 
of originality and relevance of the publication. 
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LEGENDS 
Figure 1: Temporal trends in epilepsy surgery 
A) Data from the Nationwide Inpatient Sample, which includes databases from a 20% 
random-sample of all non-federal USA hospitals, reported that the absolute number of 
lobectomies for epilepsy has not increased over time while the number of hospitalisations 
for focal epilepsy has paradoxically increased. The dashed line represents the year of 
publication of the first randomised controlled trial of epilepsy surgery.22 Reproduced 
from Englot,89 by permission of Wolters Kluwer. 
B) The number of epilepsy surgeries performed at high-volume epilepsy centres has 
decreased over time, while the number of hospitalisations for focal epilepsy at low-and 
middle-volume centres has increased by 235-300%. These hospitalizations in low- and 
middle-volume centres, however, less often result in a lobectomy, relative to high-volume 
centres. Reproduced from Englot,48 by permission of the American Association of 
Neurological Surgeons. 
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Figure 2: Strategies to increase referral for epilepsy surgery 
Footnote: *including self-efficacy and self-management tools; **consider electronic clinical 
practice guidelines; EMR = electronic medical record; MD = medical doctor; mgt = 
management; PWE = person with epilepsy
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Table 1: Indications for an epilepsy surgery evaluation16 
• Any patient with drug resistant epilepsy 
• Any patient with a complex epilepsy syndrome or requiring a complex surgical 
intervention for epilepsy 
• Patients with stereotyped seizures who also have focal findings (on EEG, MRI brain, etc.) 
• Any child with a surgically accessible MRI lesion with or without seizures 
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Table 2: Resective and non-resective interventions for temporal lobe epilepsy 
 Advantages Disadvantages 
Anterior temporal lobectomy22,23 Supported by class I evidence; best 
seizure outcomes 
Largest incision and craniotomy; 
questionable neuropsychological 
implications of lateral cortex resection 
Selective 
amygdalohippocampectomy28-31 
Preservation of lateral cortex; 
smaller incision and craniotomy 
Possibly worse seizure outcomes than 
ATL; still requires open surgery 
Transsylvian approach Complete preservation of lateral 
cortex 
Technically challenging; damage to 
temporal stem 
Transcortical approach Technically less challenging Damage to lateral cortex 
Subtemporal approach Avoids both sylvian fissure and 
lateral cortex 
Possible retraction damage to basal 
temporal lobe 
Gamma knife surgery53 No invasive surgery Antiseizure effects delayed by 12-24 
months 
Stereotactic laser thermo-
ablation54 
Only burr hole required; 
preliminarily favourable 
neuropsychological outcomes 
Higher risk of persistent seizures than 
resection; long-term outcomes require 
further study 
Device implantation No brain resection Palliative; worse seizure outcomes than 
resection/ablation 
Responsive 
neurostimulation59-61 
Direct closed-loop therapy to EZ EZ localisation required; seizure freedom 
is rare 
Vagus nerve 
stimulation64-69 
EZ localisation not required Seizure freedom is rare 
Deep brain stimulation62 EZ localisation not required Seizure freedom is rare 
Reproduced from Chang,70 by permission of Elsevier. 
EZ: epileptogenic zone 
Table 3: Possible explanations for the apparent decrease in epilepsy surgery 
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• Spurious observations due to incomplete or biased data  
• Decreasing facilitators and/or worsening barriers 
• Depletion of eligible candidates from the general population 
o Improved efficacy of newer generation antiepileptic drugs96-98 
o Increasing number of successful surgeries among children90,93,99 
o Improved management of febrile seizures and febrile status epilepticus84,93,94 
• Redistribution of pre-surgical evaluations from high-volume centres to low- and middle-
volume centres 
o As compared to high-volume centres, these are less likely to proceed to surgery due 
to more limited resources and expertise48,92 
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Table 4: Possible barriers associated with epilepsy surgery 
 Barriers 
Patient/family 
factors 
• Lack of knowledge about and misconceptions about epilepsy surgery 
o Lower educational attainment105 
o Poor health literacy and language barrier106 
o Self-perceived stigma106 
o Misconceptions, fear and anxiety about risks of epilepsy 
surgery14,100,104-109 
• Poor behaviours/cultural issues 
o Poor self-efficacy106 
o Poor self-management106  
o Parents wanting their children to be old enough to be 
involved in surgical decision making110  
o Mistrust of physician105,106 
• Access issues 
o Lack of transportation106 
o Unable to miss work106 
o Unable to miss school106 
o Lack of child care to attend appointments/be admitted106 
o Disparities  
 Age (less likely to be operated if older)100,114 
 Race (less likely to be operated if non-white)89,100,114 
 IQ (less likely to be operated if lower IQ)116 
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 Comorbidity (e.g. psychiatric comorbidity often 
higher in non-surgical group)100,106 
 Insurance status (e.g. shorter time to surgery and 
greater odds of receiving surgery if private insurance 
versus Medicaid)89,100,114 
• Research gaps 
o Insufficient knowledge and/or understanding about 
mechanisms responsible for refusal to have epilepsy surgery 
Physician/health 
system factors 
• Lack of knowledge about and misconceptions about epilepsy 
surgery14,106,110,111,113 
o Definition of drug-resistance 
o Indications for epilepsy surgery 
o Misconceptions about surgical risks 
• Poor behaviours/cultural issues 
o Negative attitudes about epilepsy surgery105 
o Not referring due to:108 
 No benefits if refer 
 No means to increase capability or opportunity 
 Lack of environmental resources to facilitate referrals 
o Poor patient-physician relationship 
o Poor communication between epileptologists and community 
physicians (i.e. primary care and neurologists)14 
• Access issues 
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o Lack of epilepsy surgery programme in their region 
o Inadequate health resources112,113 
o Complex health insurance programmes/policies 
• Research gaps 
o Need better diagnostic tools to more optimally delineate 
extent of epileptogenic zone 
o Lack of comparative effectiveness studies about surgical 
approaches (e.g. resective vs neuromodulation vs ablative) 
o Lack of evidence regarding optimal extent of resection to 
optimize seizure outcome but minimize adverse events (e.g. 
SAH vs temporal lobectomy?) 
o Need more non-invasive surgical approaches 
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